BR112013030473A2 - meios e métodos para diagnóstico e tratamento de esclerose múltipla - Google Patents

meios e métodos para diagnóstico e tratamento de esclerose múltipla

Info

Publication number
BR112013030473A2
BR112013030473A2 BR112013030473A BR112013030473A BR112013030473A2 BR 112013030473 A2 BR112013030473 A2 BR 112013030473A2 BR 112013030473 A BR112013030473 A BR 112013030473A BR 112013030473 A BR112013030473 A BR 112013030473A BR 112013030473 A2 BR112013030473 A2 BR 112013030473A2
Authority
BR
Brazil
Prior art keywords
sequence
multiple sclerosis
peptide
predisposition
methods
Prior art date
Application number
BR112013030473A
Other languages
English (en)
Inventor
Bernhard Hemmer
Rajneesh Srivastava
Original Assignee
Klinikum Rechts Der Isar Der Tecnnischen Universität München
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinikum Rechts Der Isar Der Tecnnischen Universität München filed Critical Klinikum Rechts Der Isar Der Tecnnischen Universität München
Publication of BR112013030473A2 publication Critical patent/BR112013030473A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)

Abstract

1/1 resumo esta invenção se refere a um peptídeo compreendendo ou consistindo em pelo menos 8 resíduos de aminoácidos consecutivos da sequência definida 5 na seq id no: 3, desde que o referido peptídeo não consista na sequência definida na seq id no: 3, ou um peptidomimético correspondente, em que o referido peptídeo ou peptidomimético se liga a um anticorpo antikir4.1 compreendido numa amostra de um paciente, o referido paciente possuindo esclerose múltipla ou uma predisposição para a mesma, em que 10 preferivelmente (i) os referidos pelo menos 8 resíduos de aminoácidos consecutivos são uma subsequência de um domínio extracelular de kir4.1, o referido domínio extracelular consistindo na sequência definida na seq id no: 1 ou 2; ou (ii) o referido peptídeo compreende ou consiste na sequência de seq id no: 1 ou 2. a presente invenção se refere, além 15 disso, a um método para diagnóstico de esclerose múltipla ou uma predisposição para esclerose múltipla em um sujeito, o método compreendendo a determinação da presença de um anticorpo anti-kir4.1 em uma amostra obtida a partir do referido sujeito, em que a presença de um anticorpo anti-kir4.1 na referida amostra é indicativa de esclerose 20 múltipla ou uma predisposição para esclerose múltipla. são também proporcionados novos meios e métodos para a terapia de esclerose múltipla.
BR112013030473A 2011-05-30 2012-05-23 meios e métodos para diagnóstico e tratamento de esclerose múltipla BR112013030473A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11004423A EP2530088A1 (en) 2011-05-30 2011-05-30 Means and methods for diagnosing and treating multiple sclerosis
PCT/EP2012/059622 WO2012163765A1 (en) 2011-05-30 2012-05-23 Means and methods for diagnosing and treating multiple sclerosis

Publications (1)

Publication Number Publication Date
BR112013030473A2 true BR112013030473A2 (pt) 2016-11-29

Family

ID=45418833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030473A BR112013030473A2 (pt) 2011-05-30 2012-05-23 meios e métodos para diagnóstico e tratamento de esclerose múltipla

Country Status (13)

Country Link
US (2) US9297809B2 (pt)
EP (2) EP2530088A1 (pt)
JP (2) JP6316746B2 (pt)
KR (1) KR102021107B1 (pt)
CN (1) CN103687871B (pt)
AU (1) AU2012264943B2 (pt)
BR (1) BR112013030473A2 (pt)
CA (1) CA2832391C (pt)
DK (1) DK2714729T3 (pt)
IL (1) IL229704A (pt)
MX (1) MX343630B (pt)
RU (1) RU2601298C2 (pt)
WO (1) WO2012163765A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015254596B2 (en) * 2014-04-30 2020-10-22 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Diagnosis of multiple sclerosis
WO2017062682A2 (en) * 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
RU2648215C1 (ru) * 2017-03-01 2018-03-22 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ дифференциальной диагностики органических поражений цнс у детей в остром периоде
CN108853505B (zh) * 2017-05-09 2022-02-25 浙江大学 钾离子通道抑制剂治疗抑郁症的用途和药物组合物
KR102282341B1 (ko) * 2018-09-12 2021-07-27 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
RU2741929C1 (ru) * 2020-06-19 2021-01-29 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционный болезней Федерального медико-биологического агентства" Способ прогнозирования риска развития энцефалопатии критических состояний у детей с инфекционными заболеваниями
WO2023056387A1 (en) * 2021-09-29 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Diagnosing multiple sclerosis (ms)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7262290B2 (en) * 2000-08-28 2007-08-28 Trustees Of The University Of Pennsylvania Diagnostic markers for multiple epilepsy phenotypes
JP2003079270A (ja) * 2001-09-10 2003-03-18 Japan Science & Technology Corp ミエリン発達障害モデル非ヒト動物
RU2214839C2 (ru) * 2001-10-26 2003-10-27 Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН Способ лечения рассеянного склероза
RU2369874C2 (ru) * 2002-08-02 2009-10-10 Гликоминдс Лтд. Способ диагностики рассеянного склероза
US9353190B2 (en) * 2006-03-30 2016-05-31 The Board Of Trustees Of The Leland Stanford Junio Compositions, systems and methods for the diagnosis, prevention and treatment of disorders associated with azetidine-2-carboxylic acid
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
EP2488196B1 (en) 2009-10-12 2015-12-16 LIFEBio Laboratories LLC Composition for treatment of multiple sclerosis
US9732138B2 (en) * 2010-02-09 2017-08-15 Yale University Loss of function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
WO2012094394A2 (en) * 2011-01-04 2012-07-12 Yale University Methods and compositions for assessing and treating adrenal diseases and disorders

Also Published As

Publication number Publication date
JP2018058852A (ja) 2018-04-12
JP6316746B2 (ja) 2018-04-25
CA2832391A1 (en) 2012-12-06
US20160161482A1 (en) 2016-06-09
US9297809B2 (en) 2016-03-29
RU2601298C2 (ru) 2016-10-27
CN103687871B (zh) 2016-03-02
WO2012163765A1 (en) 2012-12-06
US9733244B2 (en) 2017-08-15
CN103687871A (zh) 2014-03-26
IL229704A0 (en) 2014-01-30
RU2013158334A (ru) 2015-07-10
CA2832391C (en) 2019-10-29
EP2714729B1 (en) 2020-01-01
MX343630B (es) 2016-11-14
DK2714729T3 (da) 2020-03-16
AU2012264943A1 (en) 2013-10-17
JP2014523869A (ja) 2014-09-18
EP2530088A1 (en) 2012-12-05
MX2013013931A (es) 2014-04-25
EP2714729A1 (en) 2014-04-09
AU2012264943B2 (en) 2016-12-15
NZ615912A (en) 2016-05-27
US20140080156A1 (en) 2014-03-20
IL229704A (en) 2017-12-31
KR102021107B1 (ko) 2019-09-11
NZ717188A (en) 2017-08-25
KR20140043892A (ko) 2014-04-11

Similar Documents

Publication Publication Date Title
BR112013030473A2 (pt) meios e métodos para diagnóstico e tratamento de esclerose múltipla
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
BR112014012101A2 (pt) métodos de tratamento de artrite psoriática (psa) usando os antagonistas de il- 17 e alelos de resposta ou não resposta à psa
BR112013033488A2 (pt) marcadores biológicos de micro-rna indicativo da doença de alzheimer
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112014007687A8 (pt) Composiçâo farmacêutica de anticorpos para eliminação de antígenos no plasma
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112017017076A2 (pt) inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre.
BR112014009528A8 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112018071583A2 (pt) métodos para determinar dpp3 e métodos terapêuticos
ES2621809T3 (es) Inhibidores de TFPI y procedimientos de uso
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
AR081696A1 (es) Anticuerpo para el diagnostico y/o pronostico de cancer
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
BR112013010918B8 (pt) composição compreendendo sal de cloridrato de alumínio, método de fabricação do referido sal e usos do mesmo
DOP2017000248A (es) PROTEÍNA DE UNIÓN A RGMa Y SU USO
BR112018013861A2 (pt) polipeptídeo, complexo, composição farmacêutica, métodos para tratar um distúrbio de coagulação sanguínea, para produzir um polipeptídeo e um dímero de um polipeptídeo, para aumentar a meia vida do fator viii e para aumentar a dimerização do dito polipeptídeo, uso de um polipeptídeo, kit farmacêutico, plasmídeo ou vetor, e, célula hospedeira
BR112014005573A2 (pt) Anticorpo monoclonal b7-h6 terapeuticamente ativo contra polipeptídeo b7-h6
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
BRPI0706575B8 (pt) uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
BR112015018035A2 (pt) anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno
BR112017020769A2 (pt) anticorpo ou fragmento de ligação, seq id no:3 ou seq id no:7, conjugado de anticorpo-fármaco (adc), composição farmacêutica, processo para produzir a composição farmacêutica, kit para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, método para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, uso do anticorpo ou fragmento de ligação, uso ex vivo de um peptídeo t14, método para identificar um agente candidato, ensaio para identificar um agente, método para identificar um agente que modula
BR112021013096A2 (pt) Tratamento de doença de sjögren com proteínas de fusão de nuclease
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements